• CXCR4–EGFR Heteromers Rewire Cancer Signaling

  2026-09-02

  Comez et al. show that CXCR4 and EGFR assemble into ligand-responsive oligomeric signaling complexes rather than functioning only as independent receptors. NanoBRET, nanobody-based proximity ligation assays, and functional coupling measurements link these complexes to PLCγ, Gi proteins, and β-arrestin-2, with endogenous receptor proximity confirmed in HeLa cells.

• Gefitinib (ZD1839) for Cancer Assembloid Studies

  2026-09-02

  Use Gefitinib (ZD1839) as a mechanistic EGFR probe in matched tumor organoids and stromal-integrated assembloids, not only in conventional monolayers. This workflow helps distinguish direct tumor-cell sensitivity from microenvironment-driven resistance while connecting phospho-signaling data to viability, cell-cycle, and apoptosis outcomes.

• Tunicamycin and the UPR: Calibrating ER Stress

  2026-09-01

  Tunicamycin is a powerful N-glycosylation inhibitor for dissecting adaptive versus damaging ER stress. This article translates new C. elegans cadmium-resistance findings into practical assay logic without treating UPR activation as a simple on-or-off endpoint.

• Estradiol Workflows for Receptor–Autophagy Studies

  2026-09-01

  Build reproducible Estradiol assays that separate ERα and ERβ activity from vehicle effects, exposure artifacts, and autophagy-specific changes. This workflow translates multi-organ aging evidence into practical cell-based, pathway, and validation experiments.

• Norovirus Co-opts NINJ1 for Selective Secretion

  2026-08-31

  Song et al. show that murine norovirus exploits the host membrane-rupture protein NINJ1 to release the viral immune-modulatory protein NS1 through a caspase-3-dependent unconventional secretion route. The study combines CRISPR screening, imaging, protein mutagenesis, and mouse infection experiments to distinguish selective viral cargo release from the broader damage-associated molecular pattern release associated with cell death.

• Toremifene Workflows for Prostate Cancer Research

  2026-08-31

  Build reproducible Toremifene dose–response, calcium-signaling, and invasion assays for hormone-responsive cancer research. This workflow separates established product specifications from testable hypotheses involving the TSPAN18–STIM1 axis, helping researchers avoid overinterpreting pharmacological effects.

• JNJ-26854165 (Serdemetan) in Cancer Research

  2026-08-30

  JNJ-26854165, also called Serdemetan, is a small-molecule HDM2 antagonist that increases p53 pathway activity by limiting HDM2-mediated protein degradation. Product-reported benchmarks support its use as an anti-proliferative agent, apoptosis inducer, and radiosensitizer in tumor xenografts, while orthogonal assay design is needed to distinguish growth arrest from cell death.

• Isoproterenol Sulfate Dihydrate: Assay Logic

  2026-08-29

  Isoproterenol sulfate dihydrate provides a defined beta-adrenergic challenge for human pacemaker and neuro-cardiac models. This article shows how to use it as a mechanistic assay layer alongside SAN–cardiac plexus assembloids rather than treating beta stimulation as a substitute for innervation.

• SR-202: PPARγ Antagonist Workflow Guide

  2026-08-28

  SR-202 gives researchers a selective way to test whether PPARγ activity drives adipocyte differentiation, insulin resistance, or macrophage-state changes. This workflow guide connects nuclear-receptor pharmacology with obesity research and the PPARγ/STAT pathway while emphasizing controls, solvent handling, and interpretation limits.

• BRD4770: G9a Histone Methyltransferase Inhibitor

  2026-08-28

  BRD4770 is a research-focused G9a histone methyltransferase inhibitor for connecting H3K9 methylation changes with senescence, cell death, and cancer-cell growth. This workflow-oriented guide shows how to build dose-response, chromatin, and phenotype assays while managing the compound’s reported insolubility.

• Gastric Cancer Assembloids Reveal Stromal Drug Effects

  2026-08-27

  A 2025 Cancers study developed patient-derived gastric cancer assembloids by combining matched tumor organoids with tumor-associated stromal subpopulations. The model revealed that stromal context alters gene expression and drug sensitivity, creating a more informative platform for resistance studies and personalized targeted therapy research.

• IRG1–Itaconic Acid Control of TBK1 and IFN-I

  2026-08-27

  A 2025 Cell Reports study identifies the IRG1–itaconic acid axis as a metabolic feedback mechanism that restrains TBK1-driven type I interferon responses. By showing that itaconic acid alkylates TBK1 at Cys605 and disrupts dimerization, the authors establish a mechanistic link between immunometabolism and innate antiviral signaling and introduce ITA-5 and ITA-9 as candidate inhibitors for IFN-I-mediated hyperinflammation.

• Lapatinib: From Kinase Potency to Metastasis Assays

  2026-08-26

  Lapatinib and GW572016 provide a powerful framework for connecting EGFR and HER2 inhibition with proliferation, invasion, and angiogenesis phenotypes. This guide shows how to interpret receptor expression, assay potency, and translational relevance without conflating target engagement with therapeutic response.

• Disodium bicinchoninate for Reliable Cell Assays

  2026-08-26

  Learn how Disodium bicinchoninate, SKU C6645, can support aqueous biochemical workflows, protein normalization, and orthogonal interpretation of cell viability and cytotoxicity experiments. The article combines practical assay design, compatibility checks, preparation guidance, and evidence from H2O2-stressed endothelial-cell research.

• Gefitinib in Gastric Cancer Assembloids

  2026-08-25

  Gefitinib (ZD1839) provides a practical probe for EGFR signaling pathway inhibition in patient-derived gastric cancer organoids and assembloids. By comparing matched tumor-only and tumor–stroma cultures, researchers can distinguish direct pathway sensitivity from microenvironment-driven resistance and improve apoptosis, proliferation, and biomarker workflows.

7684 records 1/513 page Next 12345 下5页 Last page